The Bivalent Bromodomain Inhibitor MT-1 Inhibits Prostate Cancer Growth
Authors:
- Sanjeev ShuklaSSSanjeev Shukla
- Carlos RiverosCRCarlos Riveros
- Mohammed Al-ToubatMAMohammed Al-Toubat
- Jonathan Chardon-RoblesJCJonathan Chardon-Robles
- Teruko OsumiTOTeruko Osumi
- Samuel SerranoSSSamuel Serrano
- Adam M. KaseAKAdam M. Kase
- Joachim L. PetitJPJoachim L. Petit
- Nathalie MeuriceNMNathalie Meurice
- Justyna GlebaJGJustyna Gleba
- John A. CoplandJCJohn A. Copland
- Jay ChauhanJCJay Chauhan
Open Access
Abstract
Bromodomains (BD) are epigenetic readers of histone acetylation involved in chromatin remodeling and transcriptional regulation of several genes including protooncogene cellular myelocytomatosis (c-Myc). c-Myc is difficult to target directly by agents due to its disordered alpha helical protein structure and predominant nuclear localization. The epigenetic targeting of c-Myc by BD inhibitors is an attractive therapeutic strategy for prostate cancer (PC) associated with increased c-Myc upregulation with advancing disease. MT-1 is a bivalent BD inhibitor that is 100-fold more potent than the first-in-class BD inhibitor JQ1. MT-1 decreased cell viability and causes cell cycle arrest in G0/G1 phase in castration-sensitive and resistant PC cell lines in a dose-dependent fashion. The inhibition of c-Myc function by MT-1 was molecularly corroborated by the de-repression of Protein Kinase D1 (PrKD) and increased phosphorylation of PrKD substrate proteins: threonine 120, serine 11, and serine 216 amino acid residues in β-Catenin, snail, and cell division cycle 25c (CDC25c) proteins, respectively. The treatment of 3D cell cultures derived from three unique clinically annotated heavily pretreated patient-derived PC xenografts (PDX) mice models with increasing doses of MT-1 demonstrated the lowest IC50 in tumors with c-Myc amplification and clinically resistant to Docetaxel, Cabazitaxel, Abiraterone, and Enzalutamide. An intraperitoneal injection of either MT-1 or in combination with 3jc48-3, an inhibitor of obligate heterodimerization with MYC-associated protein X (MAX), in mice implanted with orthotopic PC PDX, decreased tumor growth. This is the first pre-clinical study demonstrating potential utility of MT-1 in the treatment of PC with c-Myc dysregulation.Keywords
Funding Information
- U.S. Department of War (W81XWH-19-1-0745)
This publication has 29 references indexed in Scilit:
- The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous ProteinsInternational Journal of Molecular Sciences, 2016
- Small-Molecule Targeting of BET Proteins in Cancer2016
- Chromatin remodeling and bivalent histone modifications in embryonic stem cellsEMBO Reports, 2015
- Targeted therapy in cancerCancer Chemotherapy and Pharmacology, 2015
- MYC Activation Is a Hallmark of Cancer Initiation and MaintenanceCold Spring Harbor Perspectives in Medicine, 2014
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancerNature, 2014
- The future of epigenetic therapy in solid tumours—lessons from the pastNature Reviews Clinical Oncology, 2013
- Therapeutic application of monoclonal antibodies in cancer: advances and challengesBritish Medical Bulletin, 2012
- Epigenetic protein families: a new frontier for drug discoveryNature Reviews Drug Discovery, 2012
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011